OPEN END TURBO OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Market Closed - Börse Stuttgart 01:18:22 18/05/2024 am IST | ||
| 12.54 EUR | -3.46% |
|
| Current month | -28.47% | ||
| 1 month | -28.71% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 17/24/17 | 12.54 | -3.46% |
| 16/24/16 | 12.99 | -2.48% |
| 15/24/15 | 13.32 | -6.26% |
| 14/24/14 | 14.21 | +1.21% |
| 13/24/13 | 14.04 | -4.68% |
Delayed Quote Börse Stuttgart
Last update May 18, 2024 at 01:18 am IST
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | J.P. Morgan |
| WKN | JB8ZY8 |
| ISIN | DE000JB8ZY80 |
| Date issued | 15/12/2023 |
| Strike | 580.8 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 16.13 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 17.82 € |
|---|---|
| Lowest since issue | 12.54 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
445.2
USD
Average target price
462.6
USD
Spread / Average Target
+3.90%
- Stock Market
- Certificates
- Certificat
